Have a feature idea you'd love to see implemented?
Let us know!
BCDA BioCardia Inc
Price (delayed)
$2.135
Market cap
$9.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.19
Enterprise value
$5.9M
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's
Highlights
BCDA's quick ratio has soared by 200% YoY
The EPS has soared by 55% YoY and by 22% from the previous quarter
BioCardia's gross profit has plunged by 88% YoY and by 83% from the previous quarter
BioCardia's revenue has plunged by 88% YoY and by 83% from the previous quarter
Key stats
What are the main financial stats of BCDA
Market
Valuations
Earnings
Shares outstanding
4.58M
Market cap
$9.79M
Enterprise value
$5.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.65
Price to sales (P/S)
85.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
83.13
Revenue
$71,000
EBIT
-$7.72M
EBITDA
-$7.3M
Free cash flow
-$7.31M
Per share
Balance sheet
Liquidity
EPS
-$4.19
Free cash flow per share
-$2.58
Book value per share
$1.3
Revenue per share
$0.03
TBVPS
$2.22
Total assets
$6.27M
Total liabilities
$3.51M
Debt
$1.05M
Equity
$2.75M
Working capital
$2.22M
Debt to equity
0.38
Current ratio
1.78
Quick ratio
1.74
Net debt/EBITDA
0.53
Margins
Efficiency
Dividend
EBITDA margin
-10,277.5%
Gross margin
100%
Net margin
-10,876.1%
Operating margin
-10,935.2%
Return on assets
-208.4%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-225.3%
Return on sales
-10,876.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCDA stock price
How has the BioCardia stock price performed over time
Intraday
7.29%
1 week
5.96%
1 month
-20.34%
1 year
-77.41%
YTD
-78.56%
QTD
-31.57%
Financial performance
How have BioCardia's revenue and profit performed over time
Revenue
$71,000
Gross profit
$71,000
Operating income
-$7.76M
Net income
-$7.72M
Gross margin
100%
Net margin
-10,876.1%
BioCardia's gross profit has plunged by 88% YoY and by 83% from the previous quarter
BioCardia's revenue has plunged by 88% YoY and by 83% from the previous quarter
BioCardia's net income has increased by 38% YoY and by 10% from the previous quarter
BioCardia's operating income has increased by 38% YoY and by 10% from the previous quarter
Growth
What is BioCardia's growth rate over time
Valuation
What is BioCardia stock price valuation
P/E
N/A
P/B
1.65
P/S
85.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
83.13
The EPS has soared by 55% YoY and by 22% from the previous quarter
BioCardia's revenue has plunged by 88% YoY and by 83% from the previous quarter
BCDA's P/S is 80% above its last 4 quarters average of 47.2 but 6% below its 5-year quarterly average of 90.6
Efficiency
How efficient is BioCardia business performance
The ROA has grown by 25% from the previous quarter but it has contracted by 13% YoY
Dividends
What is BCDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCDA.
Financial health
How did BioCardia financials performed over time
BCDA's total assets is 78% higher than its total liabilities
BCDA's quick ratio has soared by 200% YoY
BCDA's current ratio has soared by 178% YoY
The debt is 62% smaller than the equity
BioCardia's debt to equity has soared by 166% from the previous quarter and by 118% YoY
The debt has declined by 25% year-on-year and by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.